Members of the ACCC IO Institute Executive Committee discuss the importance of standardizing education for Immunotherapy patients and how designating a champion within your practice can play a critical role in the success of irAE identification and management.(features Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPH, FASHP)
Advanced Practice Providers (APPs), such as nurse practitioners and physician assistants, play a fundamental role within medical oncology departments and the care of patients with cancer.
Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.
The non-specific adverse events of immune-based therapies, which often mimic autoimmune disorders rather than traditional cytotoxic effects, pose a significant challenge to emergency medicine providers.
Caring for patients experiencing toxicities from treatment with immune checkpoint inhibitors (ICIs) requires multidisciplinary input and coordination. Rheumatologists evaluate and treat patients experiencing a wide variety of immune-related adverse events (irAEs), including inflammatory arthritis, sicca syndrome, polymyalgia rheumatica, myositis, vasculitis, and scleroderma. It’s important for rheumatologists to know that these irAEs can vary significantly in their time of onset, severity, and treatment. Accurately diagnosing and treating rheumatic irAEs requires that providers obtain a tailored patient history and physical examination, since there are no definitive diagnostic laboratory tests for these complications.
Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.